
Opinion|Videos|May 26, 2025
Current Unmet Needs in ccRCC Diagnosis
Imaging advancements in ccRCC are crucial for predicting tumor biology and enhancing treatment strategies through molecular imaging techniques.
Advertisement
Episodes in this series

Current Gaps in Renal Mass Imaging
Main Discussion Topics:
- Current imaging cannot reliably predict tumor biology or aggressiveness.
- Need for imaging techniques that can identify aggressive lesions requiring immediate intervention
- Comparison to advances in prostate cancer with molecular imaging (prostate-specific membrane antigen [PSMA] PET)
- Desire for similar molecular imaging paradigms in kidney cancer
Key Points for Physicians:
- Contemporary imaging provides anatomic and enhancement information but limited biological insights.
- The ability to predict which tumors will become aggressive remains a significant gap.
- Prostate cancer imaging has evolved to routinely include molecular imaging (PSMA PET).
- Similar developments are needed in kidney cancer imaging.
Notable Insights:
There is a significant need for imaging that predicts biological behavior rather than just providing anatomic information.
Clinical Significance:
Developing imaging that predicts tumor biology could prevent overtreatment of indolent tumors and ensure appropriate intervention for aggressive ones.
Advertisement
Related to this article

OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.

Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.

VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.

Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.

Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.

A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.

Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Advertisement
Advertisement

